- Home
- U vs ROIV Comparison
U vs ROIV Comparison
Compare U & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | U | ROIV |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 14.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | U | ROIV |
|---|---|---|
| Price | $45.08 | $21.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $39.84 | $24.31 |
| AVG Volume (30 Days) | 7.1M | ★ 8.4M |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,803,658,000.00 | $20,329,000.00 |
| Revenue This Year | $3.29 | N/A |
| Revenue Next Year | $13.35 | $741.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.33 | $8.73 |
| 52 Week High | $52.15 | $23.47 |
Technical Indicators
Market Signals| Indicator | U | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 51.86 |
| Support Level | $44.30 | $21.60 |
| Resistance Level | $46.57 | $22.72 |
| Average True Range (ATR) | 1.88 | 0.81 |
| MACD | -0.38 | -0.11 |
| Stochastic Oscillator | 17.37 | 43.03 |
Price Performance
Historical ComparisonAbout U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.